To date, several small molecule EGFR tyrosine kinase inhibitors (TKIs) have shown clinical benefit in clinical trials and been approved for the treatment of malignancies, with especially dramatic improvements in the therapeutic outcomes in non-small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.